Suppr超能文献

因穿孔性憩室炎导致弥漫性腹膜炎行一期吻合术后保护性造口的作用—DIVERTI 2 研究(一项前瞻性多中心随机试验):研究背景和设计(nct04604730)。

Role of protective stoma after primary anastomosis for generalized peritonitis due to perforated diverticulitis-DIVERTI 2 (a prospective multicenter randomized trial): rationale and design (nct04604730).

机构信息

Department of Digestive Surgery, Rouen University Hospital, Rouen, France.

Department of Digestive Surgery, Tours University Hospital, Chambray-lès-Tours, France.

出版信息

BMC Surg. 2022 May 16;22(1):191. doi: 10.1186/s12893-022-01589-w.

Abstract

BACKGROUND

Traditionally, patients with peritonitis Hinchey III and IV due to perforated diverticulitis were treated with Hartmann's procedure. In the past decade, resection and primary anastomosis have gained popularity over Hartmann's procedure and recent guidelines recommend Hartmann's procedure in two situations only: critically ill patients and in selected patients with multiple comorbidity (at high risk of complications). The protective stoma (PS) is recommended after resection with primary anastomosis, however its interest has never been studied. The aim of this trial is to define the role of systematic PS after resection and primary anastomosis for peritonitis Hinchey III and IV due to perforated diverticulitis.

METHODS/DESIGN: This DIVERTI 2 trial is a multicenter, randomized, controlled, superiority trial comparing resection and primary anastomosis with (control group) or without (experimental group) PS in patients with peritonitis Hinchey III and IV due to perforated diverticulitis. Primary endpoint is the overall 1 year morbidity according to the Clavien-Dindo classification of surgical complications. All complications occurring during hospitalization will be collected. Late complications occurring after hospitalization will be collected during follow-up. In order to obtain 80% power for a difference given by respective main probabilities of 67% and 47% in the protective stoma and no protective stoma groups respectively, with a two-sided type I error of 5%, 96 patients will have to be included in each group, hence 192 patients overall. Expecting a 5% rate of patients not assessable for the primary end point (lost to follow-up), 204 patients will be enrolled. Secondary endpoints are postoperative mortality, unplanned reinterventions, incisional surgical site infection (SSI), organ/space SSI, wound disruption, anastomotic leak, operating time, length of hospital stay, stoma at 1 year after initial surgery, quality of life, costs and quality-adjusted life years (QALYs).

DISCUSSION

The DIVERTI 2 trial is a prospective, multicenter, randomized, study to define the best strategy between PS and no PS in resection and primary anastomosis for patients presenting with peritonitis due to perforated diverticulitis.

TRIAL REGISTRATION

ClinicalTrial.gov: NCT04604730 date of registration October 27, 2020. https://clinicaltrials.gov/ct2/show/NCT04604730?recrs=a&cond=Diverticulitis&draw=2&rank=12 .

摘要

背景

传统上,因穿孔性憩室炎导致的 III 期和 IV 期腹膜炎患者采用 Hartmann 手术治疗。在过去十年中,与 Hartmann 手术相比,切除和一期吻合术越来越受欢迎,最近的指南仅推荐在两种情况下使用 Hartmann 手术:重症患者和有多种合并症(并发症风险高)的患者。切除和一期吻合术后建议行保护性造口术(PS),但 PS 的作用尚未得到研究。本试验旨在确定系统行 PS 对因穿孔性憩室炎导致的 III 期和 IV 期腹膜炎患者行切除和一期吻合术的作用。

方法/设计:本 DIVERTI 2 试验是一项多中心、随机、对照、优效性试验,比较因穿孔性憩室炎导致的 III 期和 IV 期腹膜炎患者行切除和一期吻合术时(对照组)与行(实验组)与不行 PS 的差异。主要终点是根据外科并发症的 Clavien-Dindo 分类评估的总体 1 年发病率。所有住院期间发生的并发症均予收集。住院后发生的迟发性并发症在随访期间收集。为了在保护性造口组和无保护性造口组的各自主要概率分别为 67%和 47%的情况下获得 80%的统计学效能,且双侧Ⅰ类错误为 5%,每组需要纳入 96 例患者,因此总共需要纳入 192 例患者。考虑到 5%的患者无法评估主要结局(失访),需要纳入 204 例患者。次要终点是术后死亡率、非计划性再次手术、切口手术部位感染(SSI)、器官/腔隙 SSI、切口裂开、吻合口漏、手术时间、住院时间、初次手术后 1 年时的造口、生活质量、成本和质量调整生命年(QALYs)。

讨论

DIVERTI 2 试验是一项前瞻性、多中心、随机研究,旨在确定穿孔性憩室炎患者行切除和一期吻合术时行 PS 与不行 PS 的最佳策略。

试验注册

ClinicalTrials.gov:NCT04604730,注册日期 2020 年 10 月 27 日,https://clinicaltrials.gov/ct2/show/NCT04604730?recrs=a&cond=Diverticulitis&draw=2&rank=12。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3a0/9112494/14f7f4f7cba0/12893_2022_1589_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验